Lumos Pharma to Participate in September Investor Conferences

Rhea-AI Summary

Lumos Pharma, a clinical-stage biopharmaceutical company, will participate in two major conferences in September. The H.C. Wainwright 23rd Annual Global Investment Conference will be held from September 13-15, featuring a pre-recorded presentation available from September 13 at 7:00 AM ET. Additionally, the Cantor Virtual Global Healthcare Conference is scheduled for September 27-30, with a live fireside chat on September 29 from 4:00-4:30 PM ET. Lumos Pharma focuses on developing therapeutics for rare diseases, including its lead candidate, LUM-201, for Pediatric Growth Hormone Deficiency.

AUSTIN, Texas, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will participate in the H.C. Wainwright 23^rd Annual Global Investment Conference and the Cantor Virtual Global Healthcare Conference in September.

Event:	H.C. Wainwright 23rd Annual Global Investor Conference – September 13-15
Presentation:	Pre-recorded presentation available beginning September 13 at 7:00 AM (ET)
Webcast link:	Here
Event:	Cantor Virtual Global Healthcare Conference – September 27-30
Presentation:	Live fireside chat September 29 from 4:00-4:30 PM (ET)
Webcast link:	Here

The webcasts for each presentation can also be found on the Company’s website under “Events & Presentations” in the Investors & Media section where a replay of each presentation will be also be available. Please contact your H.C. Wainwright or Cantor salesperson, or Lumos Pharma Investor Relations, to schedule one-on-one meetings with the management team during the conferences or thereafter.

About Lumos Pharma

Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. Lumos Pharma was founded and is led by a management team with longstanding experience in rare disease drug development and received early funding from leading healthcare investors, including Deerfield Management, a fund managed by Blackstone Life Sciences, Roche Venture Fund, New Enterprise Associates (NEA), Santé Ventures, and UCB. Lumos Pharma’s lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule, currently being evaluated in a Phase 2 clinical trial, the OraGrowtH210 Trial, and a PK/PD trial, the OraGrowtH212 Trial, for the treatment of Pediatric Growth Hormone Deficiency (PGHD). If approved by the FDA, LUM-201 would provide an orally administered alternative to daily injections that current PGHD patients endure for many years of treatment. LUM-201 has received Orphan Drug Designation in both the US and EU. For more information, please visit https://lumos-pharma.com/.

Investor & Media Contact:

Lisa Miller
Lumos Pharma Investor Relations
512-792-5454
ir@lumos-pharma.com

Source: Lumos Pharma, Inc.

FAQ

What are the dates for the H.C. Wainwright 23rd Annual Global Investment Conference for LUMO?

The H.C. Wainwright 23rd Annual Global Investment Conference will take place from September 13 to September 15.

When will Lumos Pharma's pre-recorded presentation be available during the H.C. Wainwright conference?

The pre-recorded presentation will be available starting September 13 at 7:00 AM ET.

What is the schedule for the Cantor Virtual Global Healthcare Conference involving LUMO?

The Cantor Virtual Global Healthcare Conference is scheduled for September 27-30, with a live fireside chat on September 29 from 4:00-4:30 PM ET.

Where can I find Lumos Pharma's webcasts for their presentations?

Lumos Pharma's webcasts for their presentations can be found on the Company’s website under the 'Events & Presentations' section.

What is LUM-201 and what condition is it targeting?

LUM-201 is Lumos Pharma's lead therapeutic candidate targeting Pediatric Growth Hormone Deficiency (PGHD) and is currently in Phase 2 clinical trials.